Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012

Global Markets Direct, May 2012, Pages: 115

Ono Pharmaceutical Co., Ltd. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - 2012” provides data on the Ono Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ono Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ono Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ono Pharmaceutical Co., Ltd. - Brief Ono Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ono Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ono Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ono Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ono Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ono Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ono Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ono Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ono Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Keyword

Current R&D Portfolio of Ono Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd. - Key Therapeutics; Ono Pharmaceutical Co., Ltd. - Pipeline Overview and Promising Molecules; Ono Pharmaceutical Co., Ltd. - News; Ono Pharmaceutical Co., Ltd. - Latest Updates; Ono Pharmaceutical Co., Ltd. - Pipeline; Ono Pharmaceutical Co., Ltd. - Discontinued/Dormant Projects

List of Tables
List of Figures
Ono Pharmaceutical Co., Ltd. Snapshot
Ono Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Ono Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Ono Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ono Pharmaceutical Co., Ltd. – Pipeline Products Glance
Ono Pharmaceutical Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ono Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ono Pharmaceutical Co., Ltd. – Drug Profiles
Anamorelin
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Asimadoline
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Licensing and Collaboration
Carfilzomib
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Phase I - Trial Details
Phase II - Trial Details
Phase III - Trial Details
Carfilzomib + Revlimid + Dexamethasone
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
CNS 7056
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Licensing and Collaboration
Phase I - Trial Details
Phase II - Trial Details
KAI-4169
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Phase I - Trial Details
KD032
Product Description
Mechanism of Action
R&D Progress
Other Developmental Activities
ONO 6950
Product Description
Mechanism of Action
R&D Progress
ONO-2952
Product Description
Mechanism of Action
R&D Progress
ONO-4053
Product Description
Mechanism of Action
R&D Progress
ONO-4538
Product Description
Mechanism of Action
R&D Progress
ONO-5334
Product Description
Mechanism of Action
R&D Progress
ONO-7746
Product Description
Mechanism of Action
R&D Progress
ONO-9054
Product Description
Mechanism of Action
R&D Progress
ONX 0912
Product Description
Mechanism of Action
R&D Progress
Orencia
Product Description
Mechanism of Action
R&D Progress
Subcutaneous Methylnaltrexone
Subcutaneous Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Licensing and Collaboration
Phase II - Trial Details
Phase III - Trial Details
Other Developmental Activities
Ono Pharmaceutical Co., Ltd. – Pipeline Analysis
Ono Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Ono Pharmaceutical Co., Ltd. – Pipeline Products By Target
Ono Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Ono Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action
Ono Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Ono Pharmaceutical Co., Ltd. - Dormant Projects
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Arocyte
Cereact
ONO-5129
ONO-6818
Ono Pharmaceutical Co., Ltd. – Company Statement
Ono Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Ono Pharmaceutical Co., Ltd., Recent Developments
Ono Pharmaceutical Co., Ltd.- Press Release
Jun 08, 2009: Progenics Announces Initiation Of RELISTOR Clinical Trials In Japan By Ono Pharmaceutical
Jun 01, 2009: Medarex Announces Efficacy Data In Cancer Patients Treated with Investigational Anti-PD-1 Antibody At American Society Of Clinical Oncology Annual Meeting
Financial Deals Landscape
Ono Pharmaceutical Co., Ltd., Deals Summary
Ono Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Receptos Enters Into R&D Agreement With Ono Pharma
Progenra Enters Into Research Agreement With Ono Pharma
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA
Ono Pharma Extends Research Agreement With Evotec
Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex
Xention Extends Collaboration With Ono Pharma
Ono Pharma Enters Into Co-Development Agreement With BioFocus
BioSeek Enters Into Drug Discovery Collaboration With Ono Pharma
Evotec Extends Research Agreement With Ono Pharma
Ono Pharma Enters Into Research Agreement With Xention
Ono Pharma Enters Into Drug Discovery Agreement With Evotec
Ono Pharma Enters Into New Co-Development Agreement With Locus Pharma
BioFocus Enters Into Co-Development Agreement With Ono Pharma
Ono Pharma Enters Into Co-Development Agreement With Locus Pharma
Ono Pharma Enters Into Research Agreement With Medarex
Ono Pharma Enters Into Agreement With Dainippon Sumitomo Pharma
Ono Pharma Enters Into Co-Development Agreement With Array Biopharma
Discovery Partners Enters Into Collaboration With Ono Pharma
Ono Pharma Enters Into Research Agreement With Medarex
Licensing Agreements
Ono Pharma Enters Into Licensing Agreement With CeNeS Pharma
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine
Ono Pharma Enters Into Licensing Agreement With OncoTherapy
Onyx Pharma Enters Into Licensing Agreement With Ono Pharma For Carfilzomib And ONX 0912
Concordia Pharma Enters Into Licensing Agreement With Ono Pharma For Salirasib
Tioga Pharma Enters Into Licensing Agreement With Ono Pharma
Ono Pharma Enters Into Licensing Agreement With Progenics Pharma
Ono Pharma Enters Into Licensing Agreement With Nissan Chemical Industries
Ono Pharma Enters Into Licensing Agreement With Sapphire Therapeutics
Ono Pharma Enters Into Licensing Agreement With Santen Pharma
Ono Pharma Enters Into Agreement With Novartis Pharma
Ono Pharma Enters Into Licensing Agreement With Merck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ono Pharmaceutical Co., Ltd., Key Information
Ono Pharmaceutical Co., Ltd., Key Facts
Ono Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012
Ono Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012
Ono Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012
Ono Pharmaceutical Co., Ltd. – Phase III, 2012
Ono Pharmaceutical Co., Ltd. – Phase II, 2012
Ono Pharmaceutical Co., Ltd. – Phase I, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, 2012
Ono Pharmaceutical Co., Ltd. - Pipeline By Target, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline Products By Mechanism of Action, 2012
Ono Pharmaceutical Co., Ltd. – Recent Pipeline Updates, 2012
Ono Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2012
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2012
Ono Pharmaceutical Co., Ltd., Other Locations
Ono Pharmaceutical Co., Ltd., Subsidiaries
Ono Pharmaceutical Co., Ltd., Deals Summary
Receptos Enters Into R&D Agreement With Ono Pharma
Progenra Enters Into Research Agreement With Ono Pharma
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA
Ono Pharma Extends Research Agreement With Evotec
Ono Pharma Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex
Xention Extends Collaboration With Ono Pharma
Ono Pharma Enters Into Co-Development Agreement With BioFocus
BioSeek Enters Into Drug Discovery Collaboration With Ono Pharma
Evotec Extends Research Agreement With Ono Pharma
Ono Pharma Enters Into Research Agreement With Xention
Ono Pharma Enters Into Drug Discovery Agreement With Evotec
Ono Pharma Enters Into New Co-Development Agreement With Locus Pharma
BioFocus Enters Into Co-Development Agreement With Ono Pharma
Ono Pharma Enters Into Co-Development Agreement With Locus Pharma
Ono Pharma Enters Into Research Agreement With Medarex
Ono Pharma Enters Into Agreement With Dainippon Sumitomo Pharma
Ono Pharma Enters Into Co-Development Agreement With Array Biopharma
Discovery Partners Enters Into Collaboration With Ono Pharma
Ono Pharma Enters Into Research Agreement With Medarex
Ono Pharma Enters Into Licensing Agreement With CeNeS Pharma
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax
Ono Pharma Enters Into Licensing Agreement With KAI Pharma For KAI-4169
Ono Pharma Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine
Ono Pharma Enters Into Licensing Agreement With OncoTherapy
Onyx Pharma Enters Into Licensing Agreement With Ono Pharma For Carfilzomib And ONX 0912
Concordia Pharma Enters Into Licensing Agreement With Ono Pharma For Salirasib
Tioga Pharma Enters Into Licensing Agreement With Ono Pharma
Ono Pharma Enters Into Licensing Agreement With Progenics Pharma
Ono Pharma Enters Into Licensing Agreement With Nissan Chemical Industries
Ono Pharma Enters Into Licensing Agreement With Sapphire Therapeutics
Ono Pharma Enters Into Licensing Agreement With Santen Pharma
Ono Pharma Enters Into Agreement With Novartis Pharma
Ono Pharma Enters Into Licensing Agreement With Merck

List of Figures
Ono Pharmaceutical Co., Ltd. – Pipeline by Indication, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, 2012
Ono Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, 2012
Ono Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, 2012
Ono Pharmaceutical Co., Ltd. - Pipeline By Target, 2012
Ono Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, 2012
Ono Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?
• DeNa Co Ltd,(DNACF) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• E-machitown Co Ltd,(4747) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages